Hepatotoxicity with combination of vemurafenib and ipilimumab
A Ribas, FS Hodi, M Callahan, C Konto… - New England Journal …, 2013 - Mass Medical Soc
A Ribas, FS Hodi, M Callahan, C Konto, J Wolchok
New England Journal of Medicine, 2013•Mass Medical SocHepatotoxicity with Combination of Vemurafenib and Ipilimumab | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career with
NEJM Group information and services. NEJM Evidence NEW! A digital journal for innovative
original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career with
NEJM Group information and services. NEJM Evidence NEW! A digital journal for innovative
original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
The independent mechanisms of action and largely nonoverlapping toxicity profiles of vemurafenib and ipilimumab made it logical to test them together in a study of patients with melanoma. An unexpected level of hepatic toxicity caused the early termination of the study.
The New England Journal Of Medicine